Filter Publications By:


Nat. Biotechnol. 2000; 18: 509-514.

Immunostimulatory DNA-based Vaccines Induce Cytotoxic Lymphocyte Activity by a T Helper Cell-independent Mechanism.

Cho, H.J., K. Takabayashi, P.M. Cheng, M.D. Nguyen, M. Corr, S. Tuck, and E. Raz.


Blood, 2005. 105(2):489-495.

Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkins lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity.

Friedberg, J.W., H. Kim, M. McCauley, E.M. Hessel, P. Sims, D.C. Fisher, L.M. Nadler, R.L. Coffman, and A.S. Freedman.


Clin Cancer Res. 2008;14(17):5626-34.

CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans.

Haining WN, Davies J, Kanzler H, Drury L, Brenn T, Evans J, Angelosanto J, Rivoli S, Russell K, George S, Sims P, Neuberg D, Li X, Kutok J, Morgan J, Wen P, Demetri G, Coffman RL, Nadler LM.


Br J Haematol. 2009;146(3):282-91. PMCID: PMC2747261

Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma.

Friedberg JW, Kelly JL, Neuberg D, Peterson DR, Kutok JL, Salloum R, Brenn T, Fisher DC, Ronan E, Dalton V, Rich L, Marquis D, Sims P, Rothberg PG, Liesveld J, Fisher RI, Coffman R, Mosmann T, Freedman AS.


Vaccine, 2012; 30(15): 2556-2563.

Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18–55 years of age.

Scott A. Halperin, Brian Ward, Curtis Cooper, Gerald Predy, Francisco Diaz-Mitoma, Marc Dionne, Joanne Embree, Allison McGeer, Paul Zickler, Karl-Heinz Moltz, René Martz, Ingo Meyer, Shelly McNeil, Joanne M. Langley, Eduardo Martins, William L. Heyward, J. Tyler Martin.